Singapore - English - HSA (Health Sciences Authority)

orion pharma (sg) pte. ltd. - carbidopa monohydrate 54.1mg corresponds to carbidopa; entacapone; levodopa - tablet, film coated - 50mg - carbidopa monohydrate 54.1mg corresponds to carbidopa 50mg; entacapone 200mg; levodopa 200mg

Singapore - English - HSA (Health Sciences Authority)

orion pharma (sg) pte. ltd. - carbidopa monohydrate eqv carbidopa; entacapone; levodopa - tablet, film coated - 27 mg (corresponds to 25 mg carbidopa) - carbidopa monohydrate eqv carbidopa 25 mg; entacapone 200 mg; levodopa 100 mg

Singapore - English - HSA (Health Sciences Authority)

orion pharma (sg) pte. ltd. - carbidopa monohydrate eqv carbidopa; entacapone; levodopa - tablet, film coated - 40.5 mg (corresponds to 37.5 mg carbidopa) - carbidopa monohydrate eqv carbidopa 37.5 mg; entacapone 200 mg; levodopa 150 mg

Singapore - English - HSA (Health Sciences Authority)

orion pharma (sg) pte. ltd. - carbidopa monohydrate eqv carbidopa; entacapone; levodopa - tablet, film coated - 13.5 mg (corresponds to 12.5 mg carbidopa) - carbidopa monohydrate eqv carbidopa 12.5 mg; entacapone 200 mg; levodopa 50 mg

Singapore - English - HSA (Health Sciences Authority)

orion pharma (sg) pte. ltd. - entacapone - tablet, film coated - 200 mg - entacapone 200 mg

European Union - English - EMA (European Medicines Agency)

orion corporation - entacapone - parkinson disease - anti-parkinson drugs - entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

medispec (m) sdn.bhd - entacapone -

New Zealand - English - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - carbidopa monohydrate 27mg equivalent to carbidopa 25 mg; entacapone 200mg; levodopa 100mg - film coated tablet - 100mg/25mg/200mg - active: carbidopa monohydrate 27mg equivalent to carbidopa 25 mg entacapone 200mg levodopa 100mg excipient: croscarmellose sodium ethanol glycerol hypromellose iron oxide red iron oxide yellow magnesium stearate maize starch mannitol polysorbate 80 povidone purified water sucrose titanium dioxide - the treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - carbidopa monohydrate 33.8mg equivalent to 31.25 mg carbidopa; entacapone 200mg; levodopa 125mg - film coated tablet - 125mg/31.25mg/200mg - active: carbidopa monohydrate 33.8mg equivalent to 31.25 mg carbidopa entacapone 200mg levodopa 125mg excipient: croscarmellose sodium ethanol glycerol hypromellose iron oxide red magnesium stearate   maize starch mannitol polysorbate 80 povidone purified water sucrose titanium dioxide - stalevo is indicated for the treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - carbidopa monohydrate 40.5mg equivalent to carbidopa 37.5 mg; entacapone 200mg; levodopa 150mg - film coated tablet - 150mg/37.5mg/200mg - active: carbidopa monohydrate 40.5mg equivalent to carbidopa 37.5 mg entacapone 200mg levodopa 150mg excipient: croscarmellose sodium ethanol glycerol hypromellose iron oxide red iron oxide yellow magnesium stearate maize starch mannitol polysorbate 80 povidone purified water sucrose titanium dioxide - the treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.